Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 6

1.

Non-pharmaceutical therapies for stroke: mechanisms and clinical implications.

Chen F, Qi Z, Luo Y, Hinchliffe T, Ding G, Xia Y, Ji X.

Prog Neurobiol. 2014 Apr;115:246-69. doi: 10.1016/j.pneurobio.2013.12.007. Epub 2014 Jan 7. Review.

2.

Consequences of the 118A>G polymorphism in the OPRM1 gene: translation from bench to bedside?

Mura E, Govoni S, Racchi M, Carossa V, Ranzani GN, Allegri M, van Schaik RH.

J Pain Res. 2013 May 1;6:331-53. doi: 10.2147/JPR.S42040. Print 2013.

3.

Pharmacogenetic approaches to the treatment of alcohol addiction.

Heilig M, Goldman D, Berrettini W, O'Brien CP.

Nat Rev Neurosci. 2011 Oct 20;12(11):670-84. doi: 10.1038/nrn3110. Review.

4.

Functional polymorphism of the mu-opioid receptor gene (OPRM1) influences reinforcement learning in humans.

Lee MR, Gallen CL, Zhang X, Hodgkinson CA, Goldman D, Stein EA, Barr CS.

PLoS One. 2011;6(9):e24203. doi: 10.1371/journal.pone.0024203. Epub 2011 Sep 2.

5.

A genetic determinant of the striatal dopamine response to alcohol in men.

Ramchandani VA, Umhau J, Pavon FJ, Ruiz-Velasco V, Margas W, Sun H, Damadzic R, Eskay R, Schoor M, Thorsell A, Schwandt ML, Sommer WH, George DT, Parsons LH, Herscovitch P, Hommer D, Heilig M.

Mol Psychiatry. 2011 Aug;16(8):809-17. doi: 10.1038/mp.2010.56. Epub 2010 May 18.

6.

OPRM1 SNP (A118G): involvement in disease development, treatment response, and animal models.

Mague SD, Blendy JA.

Drug Alcohol Depend. 2010 May 1;108(3):172-82. doi: 10.1016/j.drugalcdep.2009.12.016. Epub 2010 Jan 13. Review.

Supplemental Content

Support Center